Sol-Gel Technologies (SLGL) Retained Earnings (2016 - 2026)
Sol-Gel Technologies' (SLGL) quarterly Retained Earnings came in at -$240.7 million in Q1 2026, little changed year-on-year from -$241.8 million in Q1 2025, and down 1.57% on a QoQ basis from -$237.0 million in Q4 2025.
Sol-Gel Technologies (SLGL) Retained Earnings (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Retained Earnings data on file, last reported at -$240.7 million in Q1 2026.
- On a quarterly basis, Retained Earnings changed 0.44% year-over-year to -$240.7 million in Q1 2026; TTM through Mar 2026 was -$240.7 million, a 0.44% change from a year earlier, with the FY2025 full-year figure at -$237.0 million, down 2.65% from the prior year.
- Retained Earnings for Q1 2026 stood at -$240.7 million, down from -$237.0 million in the prior quarter.
- Over the last five years, Retained Earnings for SLGL reached as high as -$183.7 million in Q1 2022 and fell as low as -$240.7 million in Q1 2026.
- Historically, Retained Earnings has averaged -$216.7 million across 5 years, with a median of -$224.7 million in 2024.
- Across the five-year window, Retained Earnings rose 4.96% in 2022 and slipped 15.05% in 2023, its largest moves.
- Year by year, Retained Earnings stood at -$193.1 million in 2022, then fell by 14.11% to -$220.3 million in 2023, then retreated by 4.8% to -$230.9 million in 2024, then dropped by 2.65% to -$237.0 million in 2025, then retreated by 1.57% to -$240.7 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$240.7 million in Q1 2026, -$237.0 million in Q4 2025, and -$234.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Sol-Gel Technologies | 227.58 Mn | 217.44 Mn | - | -240.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -240.74 Mn |
| Dec 31, 2025 | -237.01 Mn |
| Sep 30, 2025 | -234.02 Mn |
| Jun 30, 2025 | -228.08 Mn |
| Mar 31, 2025 | -239.69 Mn |
| Dec 31, 2024 | -230.88 Mn |
| Sep 30, 2024 | -225.04 Mn |
| Jun 30, 2024 | -224.67 Mn |
| Mar 31, 2024 | -226.65 Mn |
| Dec 31, 2023 | -220.30 Mn |
| Sep 30, 2023 | -215.47 Mn |
| Jun 30, 2023 | -209.76 Mn |
| Mar 31, 2023 | -203.33 Mn |
| Dec 31, 2022 | -193.07 Mn |
| Sep 30, 2022 | -187.28 Mn |
| Jun 30, 2022 | -183.87 Mn |
| Mar 31, 2022 | -183.74 Mn |
| Dec 31, 2021 | -178.14 Mn |
| Sep 30, 2021 | -192.17 Mn |
| Jun 30, 2021 | -193.46 Mn |